Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
FIBROGEN INC (FGEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "FibroGen Reports Second Quarter 2023 Financial Results • Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer • Robust roxadustat volume growth of over 40% in China • Entered into exclusive license for FOR46, a first-in-class CD46-targeting antibody-drug conjugate for the treatment of metastatic castration-resistant prostate cancer • Implemented cost reduction plan extending cash runway into 2026 • Thane Wettig appointed Interim CEO"
07/25/2023 8-K Quarterly results
07/19/2023 8-K Quarterly results
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy – Study did not meet the primary endpoint – Pamrevlumab was generally safe and well tolerated – Topline results from LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with DMD expected 3Q 2023"
05/18/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia • Met primary endpoint of noninferiority of roxadustat to erythropoietin alfa • Plan to file supplemental New Drug Application in China"
05/08/2023 8-K Quarterly results
Docs: "FibroGen Reports First Quarter 2023 Financial Results • Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value • Entered Into Exclusive License for FOR46 with Fortis Therapeutics"
05/01/2023 8-K Quarterly results
02/27/2023 8-K Quarterly results
Docs: "FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results • Topline Data from Five Pivotal Phase 3 Trials in 2023 • Total Company Revenue $140.7 Million in 2022 • Continued Strong Roxadustat Volume Growth in China"
11/07/2022 8-K Quarterly results
Docs: "FibroGen Reports Third Quarter 2022 Financial Results • Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024 • Completed enrollment of MATTERHORN Phase 3 study of roxadustat in patients with anemia of myelodysplastic syndromes with topline data expected 1H 2023 • Strong roxadustat volume growth in China of over 80% vs 3Q 2021 • Announced non-dilutive royalty monetization transaction with NovaQuest for $50 million of capital secured by 22.5% of roxadustat royalty revenue in the Astellas territories"
08/08/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "FibroGen Reports Third Quarter 2021 Financial Results • Roxadustat Receives EU approval for Patients with Anemia of CKD, triggering a $120M milestone payment from Astellas • Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis"
08/27/2021 8-K Quarterly results
08/19/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Astellas Receives European Commission Approval for First-in-Class EVRENZO TM for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease Roxadustat is the first orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor available for adult patients with anemia associated with chronic kidney disease in Europe"
08/16/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer"
08/11/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease"
08/09/2021 8-K Quarterly results
Docs: "FibroGen Reports Second Quarter 2021 Financial Results"
07/20/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform"
06/25/2021 8-K Quarterly results
06/17/2021 8-K Quarterly results
06/07/2021 8-K Quarterly results
05/27/2021 8-K Quarterly results
05/14/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
04/13/2021 8-K Quarterly results
04/07/2021 8-K Quarterly results
04/06/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
12/18/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FibroGen Provides Regulatory Update on Roxadustat"
12/01/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy